PREMIO COLLAB involves hospitals, researchers and patients across Europe. A dedicated ethics team helps ensure that the research is carried out responsibly and with full respect for patients’ rights, wellbeing and privacy.
WP9 works in close collaboration with the clinical and technical partners to support the ethical conduct of the trial. This includes attention to informed consent, the clarity of patient information, and the responsible handling of issues that may arise when advanced imaging technologies are used in cancer care. Data protection and privacy are addressed together with the specialised partners responsible for GDPR and regulatory compliance.
Beyond compliance, WP9 also examines the ethical questions raised by diagnostic and monitoring technologies themselves. In particular, it investigates how patients should be informed about diagnostic uncertainty, equivocal results and incidental findings, and how clinicians can communicate these issues in ways that are transparent, respectful and clinically useful. This is especially important in metastatic cancer care, where imaging results may influence treatment decisions, expectations and patients’ understanding of their disease.
WP9 also considers how new diagnostic technologies can be fairly and responsibly introduced into healthcare systems. This includes attention to patient involvement, the ethical dimensions of reimbursement and access, and the conditions under which innovations in imaging can be implemented in ways that are beneficial, trustworthy and responsive to patients’ needs.
Through this work, WP9 contributes to the broader aim of PREMIO COLLAB: not only to develop more precise tools for cancer monitoring, but also to ensure that these tools are used in ethically sound, patient-centred and socially responsible ways.